

HCV RNA Testing and Treatment Uptake Patterns in New South Wales, Australia: A Contemporary Analysis of the Advanced DAA Era

Authors: Tillakeratne S¹, Valerio H¹, Alavi M¹, Hajarizadeh B¹, Martinello M¹, Petoumenos K¹, George J^{2,3}, Amin J^{1,4}, Matthews G¹, Grebely J¹, Pearson SA⁵, Dore G¹,

¹The Kirby Institute, UNSW, ²Storr Liver Centre, The Westmead Institute for Medical Research, Westmead Hospital, NSW, Australia ³University of Sydney, Sydney, NSW, Australia ⁴Department of Health Sciences, Faculty of Medicine and Health Sciences, Macquarie University, Sydney, NSW, Australia ⁵School of Population Health, UNSW, Australia

Background: Direct-acting antivirals (DAAs) revolutionised hepatitis C virus (HCV) treatment in Australia. This study examines treatment initiation following HCV notification during the early DAA era (2016–2018) and pangenotypic DAA era (2019–2021) in New South Wales (NSW).

Methods: HCV notifications (2010–2021) were linked to several administrative datasets including PBS treatment records (2002–2022). DAA treatment initiation, including whether treatment occurred within 4 weeks, 6 months, and 12 months of notification was assessed. Logistic regression assessed factors with treatment initiation within 6 months. Kaplan-Meier survival analysis estimated time to treatment initiation between the two eras.

Results: Estimated HCV treatment initiation at ≤6 and >6 months post-notification was 65% and 35% for those notified in 2016–2018 (n=9402) and 80% and 20% for those notified in 2019–2021 (n=6,263). In adjusted models, timely treatment (within 6 months) was associated with age <30 (aOR 1.40, 95% CI 1.14–1.73, p < 0.01), incarceration in previous 12 months (aOR 1.51, 95% CI 1.31–1.75, p < 0.001), drug dependence (receipt of OAT or injecting-related hospitalisation) in previous 12 months (aOR 1.39, 95% CI 1.22–1.58, p < 0.001), and history of end-stage liver disease (hospitalisation) (aOR 1.57, 95% CI 1.19–2.06, p = 0.001). Lower odds of timely treatment were associated with females (aOR 0.76, 95% CI 0.67–0.86, p < 0.001), overseas birth (aOR 0.79, 95% CI 0.68–0.91, p = 0.001), rural/regional residence (aOR 0.83, 95% CI 0.72–0.95, p = 0.008), and alcohol use disorder (hospitalisation) (aOR 0.88, 95% CI 0.78–0.99, p = 0.037).

Conclusion: HCV treatment initiation following notification in NSW has improved from the early to latter DAA period. However, disparities persist. Strategies addressing treatment barriers, including rural/regional residence and female gender, are essential for equitable HCV care.

Disclosure of Interest Statement: The Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine and the 2025 Conference Collaborators recognise the considerable contribution that industry partners make to professional and research activities. We also recognise the need for transparency of disclosure of potential conflicts of interest by acknowledging these relationships in publications and presentations: Greg Dore reports research support from Gilead and Abbvie. Heather Valerio has received honoraria from Gilead Sciences. Jacob George received consulting fees from NovoNordisk, AbbVie, Gilead Sciences, BMS, Pharmaxis, Novartis, Cincera, Pfizer, Roche, NovoNordisk, Eisai and Bayer. Jason Grebely has received research grants from AbbVie, Biolytical, Cepheid, Gilead and Hologic, and has received honoraria from AbbVie, Abbott, Cepheid, Gilead and Roche outside the submitted work. Marianne Martinello has received consulting fees from Abbvie.

Kathy Petoumenos reports grants from Gilead Sciences and ViiV health care. Gail Matthews reports grants from ViiV and Janssen, received honoraria from ViiV and Gilead and participated on a Data Safety Monitoring Board for ViiV. All remaining authors have no potential conflicts to declare.